ev3 takes thrombectomy catheter to the US:
This article was originally published in Clinica
ev3 has received US market approval to use its thrombus-clearing device in synthetic vessel grafts in haemodialysis patients. The X-Sizer thrombectomy catheter uses a helical cutter and vacuum to shear and remove blood thrombus from the graft without trauma, says the Plymouth, Minnesota firm. The cutter is operated by a battery-powered control unit. As a fully contained device, the system eliminates the need for large control consoles or power supplies common with other mechanical thrombus removal systems, the company claims. The device has been available for removing blood clot in coronary arteries and saphenous vein grafts for several years in Europe and other parts of the world.
You may also be interested in...
Topline results with AZD1222 have shown a lower efficacy rate than the Pfizer and Moderna vaccines, but a subgroup receiving a half-dose in their first injection showed a 90% efficacy result.
Krka’s bottom line continues to be stronger than usual, driven by a hike in sales and leaner cost base. Looking to 2021, however, management brought investors back down to earth.
The COVID-19 pandemic has triggered extraordinary levels of collaboration. But competition remains, and many newly created coalitions have yet to be stress tested.